Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2021-03-01 Capital/Financing Update
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
App 2A - quotation of shares on exercise of options 15 pages 219.2KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance and quotation of securities such as options exercised or convertible securities converted. It is a regulatory announcement related to capital markets activity, specifically the listing of new or additional securities. This type of document is not a financial report, earnings release, or management discussion, but rather a formal regulatory filing about securities quotation. According to the filing definitions, this fits best under 'Capital/Financing Update (CAP)' as it relates to updates on company fundraising, financing activities, or capital structure changes. The document is detailed and not a mere announcement of a report, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2021-03-01 English
Cleansing Notice - issue of shares upon exercise of options 1
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A of the Corporations Act regarding the issuance of shares upon exercise of options. It references an Appendix 2A and compliance with disclosure provisions but does not contain financial statements or detailed financial data. The document is short (1321 characters) and serves as a regulatory announcement about share issuance without disclosure. This fits the definition of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories like Share Issue/Capital Change (SHA) because it is a notice under a specific legal section rather than a direct capital change announcement.
2021-03-01 English
Shareholder update - year ended 31 December 2020 34 pages 2.7MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Telix Pharmaceuticals Limited dated 26 February 2021. It contains extensive information about the company's clinical programs, regulatory submissions, product pipeline, financial dashboard, and strategic outlook. The content includes forward-looking statements, clinical trial updates, regulatory filing statuses, and commercial plans. The document is structured as a comprehensive overview of the company's operations, financials, and future plans, typical of an investor presentation. There is no indication that this is an official annual report, audit report, earnings release, or regulatory filing. The presence of disclaimers, detailed program summaries, financial highlights, and strategic milestones aligns with the characteristics of an Investor Presentation (IP). The document length (15,000 characters) and detailed content further support this classification rather than a brief announcement or a regulatory filing.
2021-02-25 English
Appendix 4G - key to governance disclosures 11 pages 226.1KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3, which relate to corporate governance disclosures that must accompany the annual report. The document is a detailed key to the company's corporate governance statement, indicating compliance or non-compliance with ASX Corporate Governance Council recommendations for the financial year ended 31 December 2020. It is not the annual report itself but a governance disclosure document that accompanies or supplements the annual report. The content focuses on governance principles, board structure, and compliance with governance recommendations rather than financial results or management discussion. Given the nature of the document as a corporate governance disclosure keyed to ASX requirements, it fits best under the category 'Governance Information' (CGR). The document length (15,000 characters) and detailed content support it being a substantive governance report rather than a brief announcement or certification. Therefore, the classification is CGR with high confidence.
2021-02-25 English
Corporate Governance Statement year ended 31 December 2020 10 pages 488.8KB
Governance Information Classification · 100% confidence The document is titled 'Corporate Governance Statement Financial year ended 31 December 2020' and contains detailed information about the company's governance framework, board composition, committees, policies, and diversity objectives. It references adherence to ASX Corporate Governance Principles and Recommendations and includes descriptions of board roles, responsibilities, and performance evaluations. There is no financial data, earnings information, or audit results presented. The content focuses exclusively on governance practices and board management rather than financial reporting or announcements. Therefore, this document fits the category of Governance Information (CGR).
2021-02-25 English
Appendix 4E - Results for announcement to the market 1
Annual Report Classification · 95% confidence The document is titled as an Appendix 4E (Final Report) for the financial year ended 31 December 2020. It contains detailed financial results including revenue, net profit/loss, earnings per share, and a brief explanation of income and loss. It also references an audit report and states that the Appendix 4E and Annual Report have been approved for release by the Board of Directors. The document is 2513 characters long, which is relatively short but contains substantive financial data and analysis for the full fiscal year. Appendix 4E is typically a final report summarizing annual financial results for Australian listed companies and is closely related to the Annual Report (10-K equivalent). Given the detailed financial data and the annual period covered, this document should be classified as an Annual Report (10-K). FY 2020
2021-02-25 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.